1、Product Data Sheet(-)-EpicatechinCat. No.: HY-N0001CAS No.: 490-46-0分式: CHO分量: 290.27作靶點: COX; Ferroptosis; Endogenous Metabolite作通路: Immunology/Inflammation; Apoptosis; Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 100 mg/mL (344.51

2、mM; Need ultrasonic)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 3.4451 mL 17.2253 mL 34.4507 mL5 mM 0.6890 mL 3.4451 mL 6.8901 mL10 mM 0.3445 mL 1.7225 mL 3.4451 mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內使，-20C 儲存時，請在 1 個內使。

3、體內實驗請根據您的實驗動物和給藥式選擇適當的溶解案。以下溶解案都請先按照 In Vitro 式配制澄清的儲備液，再依次添加助溶劑：為保證實驗結果的可靠性，澄 的儲備液可以根據儲存條件，適當保存；體內實驗的作液，建議您現現配，當天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現沉淀、析出現象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (8.61 mM); Clear solution此案可獲得 2.5 mg/mL (8.61

4、 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (8.61 mM); Clear solution此案可獲得 2.5 mg/mL (8.61 mM，飽和度未知) 的澄清溶液。Page 1 of 2 www.MedChemE以 1 mL 作液為例，

5、取 100 L 25.0 mg/mL 的澄均勻。DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (8.61 mM); Clear solution此案可獲得 2.5 mg/mL (8.61 mM，飽和度未知) 的澄 溶液，此案不適于實驗周 期在半個以上的實驗。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 900 L 油中，混合均勻。BIOLOGICAL ACTIVITY物活性 (-)-Epicatechin 抑

6、制環加氧酶-1 (COX-1) , IC50為 3.2 M。(-)-Epicatechin 通過阻斷 NF-B 的 p65 亞基的核定位來抑制 IL-1 誘導的 iNOS 表達。IC & Target COX-1 Human Endogenous Metabolite3.2 M (IC50) (批量添加)體外研究 (-)-Epicatechin exhibits 95% inhibitory activity at 70 g/mL against cyclooxygenase-1 (COX-1) with an IC50 of 3.2 M1. (-)-Epicatechin inhibits

7、the IL-1-induced expression of iNOS by blocking the nuclear localization of the p65subunit of NF-B. In RINm5F cells, (-)-Epicatechin is shown to block the inhibition of insulin release after addition ofIL-1. Additionally, (-)-Epicatechin is shown to inhibit the proliferation of Hodgkins lymphoma cel

8、ls and Jurkat T cells,which is attributed to the ability of (-)-Epicatechin to inhibit the binding of NF-B to DNA in these cells. In humancolorectal cancer HCT-116 cells, combining 20 M Panaxadiol with 150, 200, or 250 M (-)-Epicatechin results ingrowth inhibition of 51%, 97%, and 95%, respectively.

9、 The combination also increases the apoptosis level by 11.9%,16.6%, and 25.8%, as examined by annexin V/PI staining2.體內研究 Animals receive 1 mg/kg of (-)-Epicatechin or water (vehicle) via oral gavage (twice daily). Exercise groups undergo 15days of treadmill exercise. Significant increases in treadm

10、ill performance (50%) and enhanced in situ muscle fatigueresistance (30%) are observed with (-)-Epicatechin3.PROTOCOLAnimal Mice3Administration 3 1-year-old, male C57BL/6N mice (n=25) are randomized into four groups. Mice in the (-)-Epicatechin groups 3 and 4 are given 1.0 mg/kg twice a day (morning

11、 and evening) for 15 consecutive days, whereas animals in the controlgroups 1 and 2 receive the vehicle (water). Both (-)-Epicatechin and vehicle are administered via oral gavage3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發表的科研獻 Int J Insect

12、Sci. 2018 Feb 28;10:1179543318758409. Viruses. 2020 Feb 4;12(2). pii: E176.See more customer validations on HYPERLINK www.MedChemE www.MedChemEPage 2 of 3 www.MedChemEREFERENCES1. Waffo-Tguo P, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (V

13、itis vinifera) cell cultures. NutrCancer. 2001;40(2):173-9.2. Shay J, et al. Molecular Mechanisms and Therapeutic Effects of (-)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, andNeurodegeneration. Oxid Med Cell Longev. 2015;2015:181260.3. Nogueira L, et al. (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle. J Physiol. 2011 Sep 15;589(Pt 18):4615-31.McePdfHeightCaution: